Equillium, Inc. announced on May 1, 2025, the advancement of EQ504, a novel and potent aryl hydrocarbon receptor (AhR) modulator, into its pipeline. This program was acquired through the acquisition of Ariagen, a company majority-owned by Equillium’s largest investor, Decheng Capital.
The acquisition terms were favorable, with no upfront payment and milestone payments commencing only upon FDA approval. EQ504 targets the AhR pathway, which is critical for barrier organ tissue physiology and immunology, maintaining barrier function and promoting tissue repair.
EQ504 possesses excellent drug-like properties, making it suitable for targeted local delivery, such as enteric coating for ulcerative colitis or inhaled formulations for inflammatory lung diseases. Equillium plans to initiate a Phase 1 study for EQ504, contingent on securing additional capital.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.